These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 17379663)

  • 1. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.
    Heidel JD; Yu Z; Liu JY; Rele SM; Liang Y; Zeidan RK; Kornbrust DJ; Davis ME
    Proc Natl Acad Sci U S A; 2007 Apr; 104(14):5715-21. PubMed ID: 17379663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.
    Davis ME
    Mol Pharm; 2009; 6(3):659-68. PubMed ID: 19267452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.
    Bartlett DW; Davis ME
    Bioconjug Chem; 2007; 18(2):456-68. PubMed ID: 17326672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles.
    Bartlett DW; Davis ME
    Biotechnol Bioeng; 2008 Mar; 99(4):975-85. PubMed ID: 17929316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
    Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
    Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pH-triggered nanoparticle mediated delivery of siRNA to liver cells in vitro and in vivo.
    Kolli S; Wong SP; Harbottle R; Johnston B; Thanou M; Miller AD
    Bioconjug Chem; 2013 Mar; 24(3):314-32. PubMed ID: 23305315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.
    Davis ME; Zuckerman JE; Choi CH; Seligson D; Tolcher A; Alabi CA; Yen Y; Heidel JD; Ribas A
    Nature; 2010 Apr; 464(7291):1067-70. PubMed ID: 20305636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
    Li SD; Huang L
    Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteinase K-containing lipid nanoparticles for therapeutic delivery of siRNA LOR-1284.
    Kim DC; Cho YA; Li H; Yung BC; Lee RJ
    Anticancer Res; 2014 Jul; 34(7):3531-5. PubMed ID: 24982365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery.
    Wang XL; Xu R; Lu ZR
    J Control Release; 2009 Mar; 134(3):207-13. PubMed ID: 19135104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice.
    Guo J; Cheng WP; Gu J; Ding C; Qu X; Yang Z; O'Driscoll C
    Eur J Pharm Sci; 2012 Apr; 45(5):521-32. PubMed ID: 22186295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of nanoparticulate drug delivery systems via the intravenous route for cancer gene therapy.
    Hallaj-Nezhadi S; Lotfipour F; Dass CR
    Pharmazie; 2010 Dec; 65(12):855-9. PubMed ID: 21284252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
    Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
    Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different mechanisms for nanoparticle formation between pDNA and siRNA using polyrotaxane as the polycation.
    Yamada Y; Hashida M; Nomura T; Harashima H; Yamasaki Y; Kataoka K; Yamashita A; Katoono R; Yui N
    Chemphyschem; 2012 Apr; 13(5):1161-5. PubMed ID: 22383277
    [No Abstract]   [Full Text] [Related]  

  • 17. siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA.
    Zuckerman JE; Gale A; Wu P; Ma R; Davis ME
    Nucleic Acid Ther; 2015 Apr; 25(2):53-64. PubMed ID: 25734248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
    Miederer M; McDevitt MR; Sgouros G; Kramer K; Cheung NK; Scheinberg DA
    J Nucl Med; 2004 Jan; 45(1):129-37. PubMed ID: 14734685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma.
    Hu-Lieskovan S; Heidel JD; Bartlett DW; Davis ME; Triche TJ
    Cancer Res; 2005 Oct; 65(19):8984-92. PubMed ID: 16204072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles.
    Carmona S; Jorgensen MR; Kolli S; Crowther C; Salazar FH; Marion PL; Fujino M; Natori Y; Thanou M; Arbuthnot P; Miller AD
    Mol Pharm; 2009; 6(3):706-17. PubMed ID: 19159285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.